Avoro Capital Advisors LLC
Institutional investor · Portfolio as of Q2 2019
Top Holdings35 positions
MIRATI THERAPEUTICS INC | 3.9M | $397.8M | 13.8% | — | — | 2 qtrssince 2019-Q1 | Unchanged 0 |
IMMUNOMEDICS INC | 21M | $291.3M | 10.1% | — | — | 2 qtrssince 2019-Q1 | Increased 72 |
IOVANCE BIOTHERAPEUTICS INC | 10.8M | $263.7M | 9.1% | $9.82 | +149.71% | 2 qtrssince 2019-Q1 | Increased 62 |
ASCENDIS PHARMA A S | 2M | $226.8M | 7.8% | $117.47 | -1.98% | 2 qtrssince 2019-Q1 | Increased 66 |
SAREPTA THERAPEUTICS INC | 1.4M | $212.7M | 7.4% | $123.99 | +22.55% | 2 qtrssince 2019-Q1 | Increased 70 |
BIOMARIN PHARMACEUTICAL INC | 2.1M | $181.2M | 6.3% | $87.33 | -1.93% | 2 qtrssince 2019-Q1 | Increased 94 |
AMARIN CORP PLC | 7.5M | $145.4M | 5.0% | $415.20 | -6.60% | 2 qtrssince 2019-Q1 | Decreased 0 |
AMICUS THERAPEUTICS INC | 10M | $124.8M | 4.3% | $13.54 | -7.86% | 2 qtrssince 2019-Q1 | Increased 59 |
ARGENX SE | 840,000 | $118.9M | 4.1% | $124.84 | +13.41% | 2 qtrssince 2019-Q1 | Unchanged 0 |
ZOGENIX INC | 2M | $96.8M | 3.3% | — | — | 2 qtrssince 2019-Q1 | Increased 59 |
HORIZON THERAPEUTICS PUB LTD | 4M | $96.2M | 3.3% | — | — | 1 qtr | New 84 |
| 2M | $92.7M | 3.2% | — | — | 2 qtrssince 2019-Q1 | Unchanged 0 | |
ATHENEX INC | 4.6M | $91.2M | 3.2% | — | — | 1 qtr | New 84 |
TRICIDA INC | 2.2M | $86.8M | 3.0% | — | — | 2 qtrssince 2019-Q1 | Increased 70 |
MYOKARDIA INC | 1.4M | $68.9M | 2.4% | — | — | 2 qtrssince 2019-Q1 | Increased 67 |
GLOBAL BLOOD THERAPEUTICS IN | 950,000 | $50M | 1.7% | — | — | 2 qtrssince 2019-Q1 | Unchanged 0 |
ADVERUM BIOTECHNOLOGIES INC | 3.5M | $41.6M | 1.4% | $118.90 | 0.00% | 1 qtr | New 68 |
MADRIGAL PHARMACEUTICALS INC | 360,000 | $37.7M | 1.3% | $122.42 | -14.38% | 2 qtrssince 2019-Q1 | Increased 54 |
ACADIA PHARMACEUTICALS INC | 1.3M | $35.4M | 1.2% | $26.85 | -0.45% | 2 qtrssince 2019-Q1 | Unchanged 0 |
BIODELIVERY SCIENCES INTL IN | 7.4M | $34.5M | 1.2% | — | — | 2 qtrssince 2019-Q1 | Unchanged 0 |
Avoro Capital Advisors LLC manages $2.9B across 35 positions as of Q2 2019. Top holdings: MRTX (13.8%), IMMU (10.1%), IOVA (9.1%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 2.5/5.0.
Active quarter - 6 new positions, 4 exits, 11 increased. Top move: BMRN (INCREASED, conviction 94). Portfolio: $2.9B across 35 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR